TP53 and acute myeloid leukemia: In a post hoc analysis of the DEC10-VEN study, patients with mutTP53 (n = 35) experienced an inferior ORR and median OS when compared with wtTP53 (n = 83): 66% versus 89% (p = 0.002) and 5.2 months versus 19.4 months (p < 0.0001), respectively.69 Among patients with mutTP53, those with multiple TP53 mutations were more likely to relapse or have refractory disease [multiple TP53 mutations were noted in 4 of 7 (57%) responding patients without a relapse versus 13 of 16 (81%) who had a relapse after a response versus 10 of 10 (100%) who had refractory AML (p = 0.049)].